Apyx Medical Corp

Apyx is headquartered in the United States and manufactures most of its products in Clearwater, Florida, while also operating a manufacturing facility in Sofia, Bulgaria. The company uses a global distributor network to sell outside the U.S., and management has specifically noted expansion of helium plasma use in cosmetic surgery markets outside the United States and in surgical oncology markets. The Clearwater site is strategically important because it supports core production, but it is also exposed to hurricane risk and other weather disruptions. Bulgaria provides geographic redundancy and access to outsourced labor-intensive assembly and sterilization support, which helps diversify manufacturing risk. Because much of the business is tied to discretionary cosmetic procedures, regional economic conditions and physician adoption rates can materially affect demand.

Apyx faces demand risk because a large part of its business depends on discretionary cosmetic and aesthetic procedures, which can weaken when consumer confidence, credit conditions, or physician capital spending deteriorate. The company also depends on regulatory clearances for new products and expanded indications, so delays or denials can slow commercialization and reduce the return on R&D spending. Supply-chain concentration is another material risk because many raw materials are single-sourced and some components and services are outsourced, making the business vulnerable to disruptions, lead-time issues, and cost inflation. Manufacturing concentration in Clearwater, Florida creates weather and hurricane exposure, while the Bulgaria facility adds cross-border operational complexity. OEM revenue is also exposed to customer ordering behavior because partners are not obligated to buy after development, which can make revenue less predictable.